Optimization of Rituximab for the Treatment of Diffuse Large B-Cell Lymphoma (II): Extended Rituximab Exposure Time in the SMARTE-R-CHOP-14 Trial of the German High-Grade Non-Hodgkin Lymphoma Study Group

Pfreundschuh Michael; Poeschel Viola; Zeynalova Samira; Haenel Mathias; Held Gerhard; Schmitz Norbert; Viardot Andreas; Dreyling Martin H.; Hallek Michael; Mueller Carsten; Wiesen Martin H. J.; Witzens-Harig Mathias; Truemper Lorenz; Keller Ulrich; Rixecker Tanja; Zwick Carsten; Murawski Niels

首页> 外文期刊>Journal of Clinical Oncology >Optimization of Rituximab for the Treatment of Diffuse Large B-Cell Lymphoma (II): Extended Rituximab Exposure Time in the SMARTE-R-CHOP-14 Trial of the German High-Grade Non-Hodgkin Lymphoma Study Group

【24h】

Optimization of Rituximab for the Treatment of Diffuse Large B-Cell Lymphoma (II): Extended Rituximab Exposure Time in the SMARTE-R-CHOP-14 Trial of the German High-Grade Non-Hodgkin Lymphoma Study Group

机译：Rituximab用于治疗弥漫性大B细胞淋巴瘤（II）的优化：德国高级非霍奇金淋巴瘤研究组的Smarte-R-Chec-14试验中的延长利妥昔单抗暴露时间

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Purpose

机译：目的

著录项

来源
《Journal of Clinical Oncology》 |2014年第36期|共8页
作者
Pfreundschuh Michael; Poeschel Viola; Zeynalova Samira; Haenel Mathias; Held Gerhard; Schmitz Norbert; Viardot Andreas; Dreyling Martin H.; Hallek Michael; Mueller Carsten; Wiesen Martin H. J.; Witzens-Harig Mathias; Truemper Lorenz; Keller Ulrich; Rixecker Tanja; Zwick Carsten; Murawski Niels;
展开▼
作者单位

Univ Klinikum Saarlandes Homburg Germany;

Univ Klinikum Saarlandes Homburg Germany;

Univ Leipzig D-04109 Leipzig Germany;

Klinikum Chemnitz Chemnitz Germany;

Univ Klinikum Saarlandes Homburg Germany;

Asklepios Klin St Georg Hamburg Germany;

Univ Ulm Klinikum Ulm Germany;

Univ Munich Klinikum Grosshadern D-80539 Munich Germany;

Univ Cologne D-50931 Cologne Germany;

Univ Cologne D-50931 Cologne Germany;

Univ Cologne D-50931 Cologne Germany;

Univ Klin Heidelberg Heidelberg Germany;

Univ Klinikum Gottingen Gottingen Germany;

Tech Univ Munich Klinikum Rechts Isar D-80290 Munich Germany;

Univ Klinikum Saarlandes Homburg Germany;

Univ Klinikum Saarlandes Homburg Germany;

Univ Klinikum Saarlandes Homburg Germany;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Optimization of Rituximab for the Treatment of Diffuse Large B-Cell Lymphoma (II): Extended Rituximab Exposure Time in the SMARTE-R-CHOP-14 Trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (vol 32, pg 4127, 2014) [J] . Pfreundschuh Journal of Clinical Oncology . 2015,第17期

机译：优化利妥昔单抗治疗弥漫性大B细胞淋巴瘤的方法（II）：德国高级别非霍奇金淋巴瘤研究组SMARTE-R-CHOP-14试验延长了利妥昔单抗的暴露时间（第32卷，第4127页， 2014）
2. Young Patients With Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma Benefit From Intensified Chemotherapy With ACVBP Plus Rituximab Compared With CHOP Plus Rituximab: Analysis of Data From the Groupe d'Etudes des Lymphomes de l'Adulte/Lymphoma Study Association Phase III Trial LNH 03-2B [J] . Molina Thierry Jo, Canioni Danielle, Copie-Bergman Christiane, Journal of Clinical Oncology . 2014,第35期

机译：非生发中心B细胞的年轻患者脱差大B细胞淋巴瘤与ACVBP Plus rituximab的加强化疗与Chop Plus Rituximab相比：来自Groupe D'Etudes des Lymphomes de L'淋巴瘤研究的数据分析协会第III期试验LNH 03-2B
3. CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). [J] . Boehme V, Schmitz N, Zeynalova S, Blood: The Journal of the American Society of Hematology . 2009,第17期

机译：使用或不使用利妥昔单抗的现代化疗（CHOP-14）治疗的老年侵袭性淋巴瘤患者的中枢神经系统事件：德国高级别非霍奇金淋巴瘤研究组（DSHNHL）RICOVER-60试验中治疗患者的分析。
4. Characterization of a rituximab variant with potent antitumor activity against rituximab-resistant B-cell lymphoma [C] . Bohua Li, Hao Wang, Yajun Guo, International conference of molecular simulations and applied informatics technologies . 2012

机译：具有抗利妥昔单抗的B细胞淋巴瘤的有效抗肿瘤活性的利妥昔单抗变体的表征
5. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
6. Rituximab plus bendamustine as front-line treatment in frail elderly (70 years) patients with diffuse large B-cell non-Hodgkin lymphoma: a phase II multicenter study of the Fondazione Italiana Linfomi [O] . Sergio Storti, Michele Spina, Emanuela Anna Pesce, 2018

机译：利妥昔单抗联合苯达莫司汀作为弱龄老年人（ 70岁）弥漫性大B细胞非霍奇金淋巴瘤患者的一线治疗：Fondazione Italiana Linfomi的II期多中心研究
7. Rituximab plus bendamustine as front-line treatment in frail elderly (>70 years) patients with diffuse large B-cell non-Hodgkin lymphoma: a phase II multicenter study of the Fondazione Italiana Linfomi [O] . Sergio Storti, Michele Spina, Emanuela Anna Pesce, 2018

机译：Rituximab Plus Bendamustine作为Frillual（> 70年）弥漫性大B细胞非霍奇金淋巴瘤患者的前线治疗患者：II期的Fondazione Italiana Linfomi的多中心研究

Optimization of Rituximab for the Treatment of Diffuse Large B-Cell Lymphoma (II): Extended Rituximab Exposure Time in the SMARTE-R-CHOP-14 Trial of the German High-Grade Non-Hodgkin Lymphoma Study Group

摘要

著录项

相似文献

相关主题

期刊订阅